Anna Nordenstrom

Prof. Anna Nordenstrom

Department of Women's and Children's Health, Karolinska Institutet

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2016 in Hormone Research in Paediatrics
Verified
Journal Article
Closed access
PLPeter A. Lee
Peter A. Lee
Anna NordenstromAnna Nordenstrom
Anna Nordenstrom
CHChristopher P. Houk
Christopher P. Houk
SAS. Faisal Ahmed
S. Faisal Ahmed
RARichard Auchus
Richard Auchus
TCthe Global DSD Update Consortium
the Global DSD Update Consortium
The goal of this update regarding the diagnosis and care of persons with disorders of sex development (DSDs) is to address changes in the clinical approach since the 2005 Consensus Conference, since knowledge and viewpoints change. An effort was made to include representatives from a broad perspective including support and advocacy groups. The goal of patient care is focused upon the best possible quality of life (QoL). The field of DSD is continuously developing. An update on the clinical evaluation of infants and older individuals with ambiguous genitalia including perceptions regarding male or female assignment is discussed. Topics include biochemical and genetic assessment, the risk of germ cell tumor development, approaches to psychosocial and psychosexual well-being and an update on support groups. Open and on-going communication with patients and parents must involve full disclosure, with the recognition that, while DSD conditions are life-long, enhancement of the best possible outcome improves QoL. The evolution of diagnosis and care continues, while it is still impossible to predict gender development in an individual case with certainty. Such decisions and decisions regarding surgery during infancy that alters external genital anatomy or removes germ cells continue to carry risk.

1 September 2009 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
LFLouise Frisén
Louise Frisén
Anna NordenstromAnna Nordenstrom
Anna Nordenstrom
Henrik FalhammarHenrik Falhammar
Henrik Falhammar
HFHelena Filipsson
Helena Filipsson
GHGundela Holmdahl
Gundela Holmdahl
ANAgneta Nordenskjöld
Agneta Nordenskjöld
Context: Gender-atypical behavior has been described in young girls as well as in women with congenital adrenal hyperplasia (CAH) due to a CYP21A2 deficiency. Objective: The aim of the study was to assess health-related, psychosexual, and psychosocial parameters and correlate the results to CYP21A2 genotype. Design and Participants: Sixty-two Swedish women with CAH and age-matched controls completed a 120-item questionnaire and a validated quality of life instrument [psychological general well-being (PGWB) formula] to identify psychosexual and psychosocial parameters. The patients were divided into four CYP21A2 genotype groups. Results: The women with CAH held more male-dominant occupations (30%) compared to controls (13%) (P = 0.04), especially those in the null genotype group (55%) (P = 0.006). They also reported a greater interest in rough sports (74%) compared to controls (50%) (P = 0.007). Eight women with CAH (14%) reported a prime interest in motor vehicles, compared to none of the controls (P = 0.002). Non-heterosexual orientation was reported by 19% of women with CAH (P = 0.005), 50% in the null genotype group (P = 0.0001), 30% in I2splice (NS), and 5% in I172N (NS). PGWB total score did not differ between patients and controls. Conclusion: We identified increased gender-atypical behavior in women with CAH that could be correlated to the CYP21A2 genotype. This speaks in favor of dose-dependent effects of prenatal androgens on the development of higher brain functions. The impact of the disease on upbringing and interpersonal relationships did not correlate with disease severity, indicating that other factors, such as coping strategies, are important for psychosocial adaptation. This illustrates the need for psychological support to parents and patients. Gender-atypical behavior in Swedish women with congenital adrenal hyperplasia is correlated to their CYP21A2 genotype.

5 December 2006 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
THTatja Hirvikoski
Tatja Hirvikoski
Anna NordenstromAnna Nordenstrom
Anna Nordenstrom
TLTorun Lindholm
Torun Lindholm
FLFrank Lindblad
Frank Lindblad
ERE. Martin Ritzén
E. Martin Ritzén
SLSvetlana Lajic
Svetlana Lajic
In Sweden, from 1985 through 1995, 40 fetuses at risk for congenital adrenal hyperplasia (CAH) were treated with dexamethasone (DEX) to prevent virilization of affected females. We report long-term effects on neuropsychological functions and scholastic performance of this controversial treatment. Prenatally treated children, 7 to 17 yr old, were assessed with standardized neuropsychological tests (A Developmental Neuropsychological Assessment and Wechsler Intelligence Scales for Children) and child-completed questionnaires measuring self-perceived scholastic competence (Self-Perception Profile for Children). A parent-completed questionnaire (Child Behavior Checklist/4-18 School Scale) was used to evaluate whether the treatment had any impact on the children's school performance. In addition, a child-completed questionnaire measuring social anxiety (The Social Anxiety Scale for Children-Revised) was completed by the prenatally treated children aged 8 to 17 yr (n = 21) and age- and sex-matched controls (n = 26). Of 40 DEX-treated children, 26 (median age, 11 yr) participated in the study. Thirty-five sex- and age-matched healthy children were controls. There were no between-group differences concerning psychometric intelligence, measures of cerebral lateralization, memory encoding, and long-term memory. Short-term treated, CAH-unaffected children performed poorer than the control group on a test assessing verbal working memory (P = 0.003), and they rated lower on a questionnaire assessing self-perception of scholastic competence (P = 0.003). This group also showed increased self-rated social anxiety assessed by The Social Anxiety Scale for Children-Revised (P = 0.026). Prenatally treated, CAH-affected children performed poorer than controls on tests measuring verbal processing speed, although this difference disappeared when controlling for the child's full-scale IQ. This study indicates that prenatal DEX treatment is associated with previously not described long-term effects on verbal working memory and on certain aspects of self-perception that could be related to poorer verbal working memory. These findings may thus question future DEX treatment of congenital adrenal hyperplasia. Therefore, we encourage additional retrospective studies of larger cohorts to either confirm or challenge the present findings.

1 November 2002 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
Anna NordenstromAnna Nordenstrom
Anna Nordenstrom
ASAnna Servin
Anna Servin
GBGunilla Bohlin
Gunilla Bohlin
ALAgne Larsson
Agne Larsson
AWAnna Wedell
Anna Wedell
Previous studies have shown that girls with congenital adrenal hyperplasia (CAH), a syndrome resulting in overproduction of adrenal androgens from early fetal life, are behaviorally masculinized. We studied play with toys in a structured play situation and correlated the results with disease severity, assessed by CYP21 genotyping, and age at diagnosis. Girls with CAH played more with masculine toys than controls when playing alone. In addition, we could demonstrate a dose-response relationship between disease severity (i.e. degree of fetal androgen exposure) and degree of masculinization of behavior. The presence of a parent did not influence the CAH girls to play in a more masculine fashion. Four CAH girls with late diagnosis are also described. Three of the four girls played exclusively with one of the masculine toys, a constructional toy. Our results support the view that prenatal androgen exposure has a direct organizational effect on the human brain to determine certain aspects of sex-typed behavior.

1 December 2014 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
Henrik FalhammarHenrik Falhammar
Henrik Falhammar
LFLouise Frisén
Louise Frisén
CNChristina Norrby
Christina Norrby
AHAngelica Lindén Hirschberg
Angelica Lindén Hirschberg
CACatarina Almqvist
Catarina Almqvist
Anna NordenstromAnna Nordenstrom
Anna Nordenstrom
Context: Reports on mortality in patients with congenital adrenal hyperplasia (CAH) are lacking.Objective: This study sought to study mortality and causes of death in CAH.Design, Setting, and Participants: We studied patients with CAH (21-hydroxylase deficiency, n = 588; CYP21A2 mutations known, >80%), and compared them with controls (n = 58 800). Data were derived through linkage of national population-based registers.Main Outcome Measures: Mortality and causes of death.Results: Mean age of death was 41.2 ± 26.9 years in patients with CAH and 47.7 ± 27.7 years in controls (P < .001). Among patients with CAH, 23 (3.9%) had deceased compared with 942 (1.6%) of controls. The hazard ratio (and 95% confidence interval) of death was 2.3 (1.2–4.3) in CAH males and 3.5 (2.0–6.0) in CAH females. Including only patients born 1952–2009, gave similar total results but only patients with salt wasting (SW) or with unclear phenotype had an increased mortality. The causes of death in patients with CAH were adrenal crisis (42%), cardiovascular (32%), cancer (16%), and suicide (10%). There were seven additional deaths in CAH individuals with incomplete or reused personal identification number that could not be analyzed using linkage of registers. Of the latter, all except one were deceased before the introduction of neonatal screening in 1986, and most of them in the first weeks of life, probably in an adrenal crisis.Conclusions: CAH is a potentially lethal condition and was associated with excess mortality due to adrenal crisis. The SW phenotype also seemed to have worse outcome in children and adults due to adrenal crisis and not only before the introduction of neonatal screening.

1 September 2013 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
SGSebastian Gidlöf
Sebastian Gidlöf
Henrik FalhammarHenrik Falhammar
Henrik Falhammar
ATAstrid Thilén
Astrid Thilén
UDUlrika von Döbeln
Ulrika von Döbeln
MRMartin Ritzén
Martin Ritzén
Anna NordenstromAnna Nordenstrom
Anna Nordenstrom